The CPH circus looks to be leaving town after Canadian listed PharmaCielo (PCLO.V) made an all-scrip AUD $122M offer to acquire Creso Pharma (CPH.ASX), which equated to AUD 0.63 per share when the deal was announced.
Muay Thai is the national sport here in my adopted homeland. Known as ‘the science of eight limbs‘ it’s a brutal contest – a knee or elbow to the head is usually enough to finish anyone off.
On the surface, the rights issue announced by Creso Pharma (CPH.ASX) looks to be a decent deal for long-suffering shareholders, albeit it a little unusual.
Confirmation bias is our tendency to cherry-pick information that confirms our existing beliefs or ideas. Think about the following statements: • Obama was not born in America. • Iraq had weapons of mass destruction. • Women are bad drivers. Do you believe any of the above statements are true?
Anyone who has followed the Creso Pharma (CPH.ASX) story over the past year was aghast when they read the recent company announcement revealing that CPH issued Assena Wealth Solutions with 1,000,000 shares as consideration for “marketing and promotional services to potential investors”
While the first snow recently dusted the streets of Vancouver, Sydneysiders have sweltered with temperatures soaring past 43 degrees Celcius (109°F) this past weekend. The financial glitterati are making the most of their last few weeks in the sun with one eye on the phone and the other on the kids.
The Hydroponics Company (THC.ASX), which listed on 4th May, is the latest cannabis outfit to tap the market for funds, halting their stock through the week to undertake an 8m+ capital raising.
The whiff of weed is in the air again, and this time it’s all about deal-making and consolidation. Joint ventures (JV) are the order of the day between listed cannabis companies and unlisted applicants.